| Ifosfamide: should the honeymoon be over? |
| BA Kamen, E Frenkel, and OM Colvin |
|
JCO Feb 1 1995: 307–309.
[PDF]
|
 |
| CNS leukemia: problem of diagnosis, treatment, and outcome |
| PG Steinherz |
|
JCO Feb 1 1995: 310–313.
[PDF]
|
 |
|
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer |
| |
B Chevallier, P Fumoleau, P Kerbrat, V Dieras, H Roche, I Krakowski, N Azli, M Bayssas, MA Lentz, and M Van Glabbeke |
| |
JCO Feb 1 1995: 314–322.
[Abstract]
[PDF]
|
 |
|
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile |
| |
KK Fields, GJ Elfenbein, HM Lazarus, BW Cooper, JB Perkins, RJ Creger, OF Ballester, JH Hiemenz, WE Janssen, and PE Zorsky |
| |
JCO Feb 1 1995: 323–332.
[Abstract]
[PDF]
|
 |
|
An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia |
| |
RC Ribeiro, GK Rivera, M Hudson, RK Mulhern, ML Hancock, L Kun, H Mahmoud, JT Sandlund, WM Crist, and CH Pui |
| |
JCO Feb 1 1995: 333–338.
[Abstract]
[PDF]
|
 |
|
Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia |
| |
SP Dibenedetto, A Di Cataldo, R Ragusa, C Meli, and L Lo Nigro |
| |
JCO Feb 1 1995: 339–344.
[Abstract]
[PDF]
|
 |
|
Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology |
| |
K Schmiegelow, H Schroder, G Gustafsson, J Kristinsson, A Glomstein, T Salmi, and L Wranne |
| |
JCO Feb 1 1995: 345–351.
[Abstract]
[PDF]
|
 |
|
Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association |
| |
C Uderzo, MG Valsecchi, A Bacigalupo, G Meloni, C Messina, P Polchi, G Di Girolamo, G Dini, R Miniero, and F Locatelli |
| |
JCO Feb 1 1995: 352–358.
[Abstract]
[PDF]
|
 |
|
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Munster Group |
| |
A Reiter, M Schrappe, R Parwaresch, G Henze, S Muller-Weihrich, S Sauter, KW Sykora, WD Ludwig, H Gadner, and H Riehm |
| |
JCO Feb 1 1995: 359–372.
[Abstract]
[PDF]
|
 |
|
CD30 (Ki-1)-positive anaplastic large-cell lymphomas in 13 patients with and 27 patients without human immunodeficiency virus infection: the first comparative clinicopathologic study from a single institution that also includes 80 patients with other human immunodeficiency virus- related systemic lymphomas |
| |
U Tirelli, E Vaccher, V Zagonel, R Talamini, D Bernardi, M Tavio, A Gloghini, MC Merola, S Monfardini, and A Carbone |
| |
JCO Feb 1 1995: 373–380.
[Abstract]
[PDF]
|
 |
|
Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas |
| |
WH Wilson, BA Chabner, G Bryant, S Bates, A Fojo, J Regis, ES Jaffe, SM Steinberg, BR Goldspiel, and BD Cheson |
| |
JCO Feb 1 1995: 381–386.
[Abstract]
[PDF]
|
 |
|
Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity |
| |
M Hill, S Milan, D Cunningham, J Mansi, I Smith, D Catovsky, M Gore, G Zulian, P Selby, and A Horwich |
| |
JCO Feb 1 1995: 387–395.
[Abstract]
[PDF]
|
 |
|
Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation |
| |
R Colwill, M Crump, F Couture, R Danish, AK Stewart, DM Sutton, JG Scott, SB Sutcliffe, JM Brandwein, and A Keating |
| |
JCO Feb 1 1995: 396–402.
[Abstract]
[PDF]
|
 |
|
Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group |
| |
R Munker, D Hasenclever, O Brosteanu, E Hiller, and V Diehl |
| |
JCO Feb 1 1995: 403–409.
[Abstract]
[PDF]
|
 |
|
Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin |
| |
Y Merrouche, S Negrier, C Bain, V Combaret, A Mercatello, B Coronel, JF Moskovtchenko, P Tolstoshev, R Moen, and T Philip |
| |
JCO Feb 1 1995: 410–418.
[Abstract]
[PDF]
|
 |
|
Rapid in vitro assay for predicting response to fluorouracil in patients with metastatic breast cancer |
| |
RM Elledge, GM Clark, J Hon, M Thant, R Belt, YP Maguire, J Brown, P Bartels, and DD Von Hoff |
| |
JCO Feb 1 1995: 419–423.
[Abstract]
[PDF]
|
 |
|
High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer |
| |
IE Smith, G Walsh, A Jones, J Prendiville, S Johnston, B Gusterson, F Ramage, H Robertshaw, N Sacks, and S Ebbs |
| |
JCO Feb 1 1995: 424–429.
[Abstract]
[PDF]
|
 |
|
Influence of prior and subsequent pregnancy on breast cancer prognosis |
| |
E von Schoultz, H Johansson, N Wilking, and LE Rutqvist |
| |
JCO Feb 1 1995: 430–434.
[Abstract]
[PDF]
|
 |
|
Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement |
| |
O Ung, AO Langlands, B Barraclough, and J Boyages |
| |
JCO Feb 1 1995: 435–443.
[Abstract]
[PDF]
|
 |
|
Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association |
| |
MH Tattersall, V Lorvidhaya, V Vootiprux, A Cheirsilpa, F Wong, T Azhar, HP Lee, SB Kang, A Manalo, and MS Yen |
| |
JCO Feb 1 1995: 444–451.
[Abstract]
[PDF]
|
 |
|
Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer |
| |
B Jeremic, Y Shibamoto, L Acimovic, and L Djuric |
| |
JCO Feb 1 1995: 452–458.
[Abstract]
[PDF]
|
 |
|
Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer |
| |
MJ Zelefsky, SA Leibel, KE Wallner, WF Whitmore, Jr, and Z Fuks |
| |
JCO Feb 1 1995: 459–463.
[Abstract]
[PDF]
|
 |
|
Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis |
| |
WR Lee, GE Hanks, TE Schultheiss, BW Corn, and MA Hunt |
| |
JCO Feb 1 1995: 464–469.
[Abstract]
[PDF]
|
 |
|
Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial |
| |
Sr Loehrer PJ, D Johnson, P Elson, LH Einhorn, and D Trump |
| |
JCO Feb 1 1995: 470–476.
[Abstract]
[PDF]
|
 |
|
Tumor angiogenesis as a predictor of recurrence in gastric carcinoma |
| |
K Maeda, YS Chung, S Takatsuka, Y Ogawa, T Sawada, Y Yamashita, N Onoda, Y Kato, A Nitta, and Y Arimoto |
| |
JCO Feb 1 1995: 477–481.
[Abstract]
[PDF]
|
 |
|
Phase I trial of escalating doses of interleukin-1 beta in combination with a fixed dose of interleukin-2 |
| |
PL Triozzi, JA Kim, EW Martin, DC Young, T Benzies, and PM Villasmil |
| |
JCO Feb 1 1995: 482–489.
[Abstract]
[PDF]
|
 |
|
Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities |
| |
DR Gandara, WA Nahhas, MD Adelson, SM Lichtman, ES Podczaski, S Yanovich, HD Homesley, P Braly, PS Ritch, and SR Weisberg |
| |
JCO Feb 1 1995: 490–496.
[Abstract]
[PDF]
|
 |
|
Multiinstitutional home-therapy trial of recombinant human interleukin- 2 and interferon alfa-2 in progressive metastatic renal cell carcinoma |
| |
J Atzpodien, E Lopez Hanninen, H Kirchner, H Bodenstein, M Pfreundschuh, U Rebmann, B Metzner, HJ Illiger, G Jakse, and T Niesel |
| |
JCO Feb 1 1995: 497–501.
[Abstract]
[PDF]
|
 |
|
The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation |
| |
GP Browman, MN Levine, EA Mohide, RS Hayward, KI Pritchard, A Gafni, and A Laupacis |
| |
JCO Feb 1 1995: 502–512.
[Abstract]
[PDF]
|
 |
|
Use of tamoxifen for breast cancer: twenty-eight years later |
| |
IA Jaiyesimi, AU Buzdar, DA Decker, and GN Hortobagyi |
| |
JCO Feb 1 1995: 513–529.
[Abstract]
[PDF]
|
 |
| CA-125 in primary mediastinal B-cell lymphoma with sclerosis |
| C Ravoet, JL Dargent, F Le Moine, and W Feremans |
|
JCO Feb 1 1995: 530–531.
[PDF]
|
 |
| Paclitaxel-induced "recall" soft tissue injury |
| GA Basler, S Desmond-Hellmann, and AP Florczyk |
|
JCO Feb 1 1995: 531a.
[PDF]
|
 |
| Myocardial ischemia and infarction associated with vinorelbine |
| A Bergeron, O Raffy, and JM Vannetzel |
|
JCO Feb 1 1995: 531b–532.
[PDF]
|
 |
| Leiomyosarcoma of the urinary bladder after cyclophosphamide |
| J Pedersen-Bjergaard, V Jonsson, M Pedersen, and K Hou-Jensen |
|
JCO Feb 1 1995: 532–533.
[PDF]
|
 |
| Second malignancies after testicular cancer |
| LB Travis, RE Curtis, and BF Hankey |
|
JCO Feb 1 1995: 533–534.
[PDF]
|
 |
| Pneumonitis related to treatment with paclitaxel |
| HL Goldberg and SB Vannice |
|
JCO Feb 1 1995: 534–535.
[PDF]
|
 |